Washington-based medical company Isoray Inc's (NYSEAMERICAN: ISR) shares are up on Wednesday after it was revealed that the company has received US Food and Drug Administration (FDA) 510 (k) clearance for the use of C4 Imaging LLC’s Sirius positive-signal MRI (Magnetic Resonance Imaging) Markers with Isoray’s Cesium-131, brachytherapy seeds.
Isoray’s stock price is up 216.68% at $1.68 per share following the news, after closing Tuesday’s session at $0.53.
Sirius is implanted during the prostate cancer treatment with brachytherapy and is used to facilitate brachytherapy seed localisation within the prostate utilising a single post-implant MRI procedure.
“This achievement represents another step forward in Isoray’s leadership in providing effective prostate cancer therapeutic tools to patients and the doctors who treat them,” commented Isoray CEO, Lori Woods.
We are excited to partner with C4 Imaging and bring together the benefits of their innovative technology and our proprietary isotope to achieve new strides in the ongoing fight against prostate cancer,” Woods added.